<DOC>
	<DOCNO>NCT00640289</DOCNO>
	<brief_summary>Congenital deficiency Factor XIII rare potentially life threaten disorder . It inherit autosomal recessive fashion . Infusion Factor XIII prove useful prevention treatment bleed episode , especially spontaneous intracranial bleeding . In study , Fibrogammin P give patient congenital Factor XIII deficiency congenital/acquired FXIII deficiency prevent bleed treat establish bleed episode . For Factor XIII prophylaxis prevent hemorrhage , dosage depend weight subject . The frequency Factor XIII administration determine factor 's circulate half-life . During first month , Factor XIII pharmacokinetic study determine 4-week period . Safety data include accrual information viral safety , liver function , complete blood count adverse event . Historical data concern spontaneous bleeds collect whenever possible two year prior treatment Fibrogammin P .</brief_summary>
	<brief_title>Clinical Trial Factor XIII ( FXIII ) Concentrate</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor XIII Deficiency</mesh_term>
	<mesh_term>Fibrinolysin</mesh_term>
	<criteria>Patients may either sex age . Children newborn infant specifically include study . Patient must document congenital Factor XIII deficiency Patient legal guardian must sign informed consent Patients negative serology hepatitis B receive Hepatitis B vaccination . Patient acquire Factor XIII deficiency</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Factor XIII Deficiency</keyword>
	<keyword>Rare Bleeding Disorder</keyword>
	<keyword>Hemophilia</keyword>
	<keyword>Fibrogammin P</keyword>
</DOC>